Labiotech.eu

Mundipharma CellAct Biliary Tract Cancer

News and Trends 14 Aug 2017

UK Pharma Pays Over €200M for a German Drug Against Biliary Cancer

Mundipharma has acquired the rights to CAP7.1, a drug that could bring the first alternative to surgery and chemo for patients with biliary tract cancer. Cambridge-based Mundipharma has paid $250M (€212M) to the German biotech CellAct in exchange for the worldwide development, commercialization and manufacturing rights to CAP7.1. The candidate is a prodrug that, when metabolized, […]

August 14, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

biotecnol cancer research uk immuno oncology

News and Trends 11 Aug 2017

Cancer Research UK Teams Up with London Startup in Immuno-oncology

Biotecnol, based in London, has found a partner in CRUK to bring its immune-stimulating antibody into the clinic to tackle solid tumors. There will (probably) be a new immuno-oncology drug on the block soon: Cancer Research UK has gone in on London startup Biotecnol‘s antibody in a deal to bring it to an open-label Phase […]

August 11, 2017 - 1 minutemin - By Evelyn Warner

galapagos glpg1690 idiopathic pulmonary fibrosis

More News! 10 Aug 2017

Belgian Biotech Takes Down Untreatable Lung Disease in Phase II, Eyes the Market

Galapagos’ GLPG1690 wowed analysts with efficacy and tolerability data in idiopathic pulmonary fibrosis treatment, opening the door to the market. Galapagos, based in Mechelen, Belgium, has reported a win in Phase IIa for its candidate GLPG1690, which aims to treat patients with idiopathic pulmonary fibrosis (IPF). The median survival is 2 to 5 years after […]

August 10, 2017 - 2 minutesmins - By Evelyn Warner

More News! 9 Aug 2017

UK Cannabinoid Company Loses 9% and a Competitor after American Phase II Failure

Zynerba Pharmaceuticals cannabinoid drug for epilepsy missed all of its endpoints costing the company’s stock price more than 55% — and GW Pharma 8.6%. On Monday, Zynerba Pharmaceuticals, a Pennsylvania-based biotech, announced that its transdermal cannabinoid candidate ZYN002 for refractory epilepsy with focal seizures had not met any of its endpoints in a Phase II […]

August 9, 2017 - 2 minutesmins - By Evelyn Warner

News and Trends 9 Aug 2017

Danish Diabetes Biotech Rakes in $75M on NASDAQ in American IPO

After announcing its intentions last month, Zealand Pharma has gone public in the US to fund its diabetes clinical trials. Zealand Pharma, a Glostrup-based biotech focused on peptide development for diabetes, has been public on the Danish Aktieselskabet exchange since 2011, and since then its share price has risen by 50%. After filing for an American […]

August 9, 2017 - 2 minutesmins - By Evelyn Warner

News and Trends 4 Aug 2017

Demo Day: Meet the Latest Generation of Synbio Startups from RebelBio

The RebelBio startups of 2017 reach a major milestone as 15 young companies came forward to explain their ideas, science and how they are selling them. A mere 3 months after the 15 chosen projects for the RebelBio accelerator went off to the labs to refine their prototypes, Demo Day arrived last week on July […]

August 4, 2017 - 6 minutesmins - By Denise Neves Gameiro

News and Trends 3 Aug 2017

Designer Babies in Europe: German Merck Set to Receive CRISPR Patent

Merck KGaA has received a Notice of Intention to Grant from the European Patent Office that its CRISPR patent will cover genomic integration. Everyone in biotech is gunning for a piece of the CRISPR pie, and German Merck will likely become the next company to acquire IP, adding to the pile it began building in 2012. […]

August 3, 2017 - 2 minutesmins - By Evelyn Warner

News and Trends 2 Aug 2017

Scottish Biotech gets €4M from Horizon 2020 for Off-the-Shelf Cell Therapy

TC Biopharm has just received the largest award of its kind to develop allogeneic gamma-delta T cell therapies for various cancers. Based in Glasgow, TC Biopharm was just selected to receive €4M from Horizon 2020 for its “off-the-shelf” gamma-delta T cell program. This grant brings the company’s fundraising total to €25M, and it’s the largest any UK […]

August 2, 2017 - 3 minutesmins - By Evelyn Warner

News and Trends 2 Aug 2017

French Biotech May Save Toddlers from Life-Threatening Peanut Allergy

The first French biotech to NASDAQ, DBV, is expanding the patient group for its promising peanut allergy treatment to include toddlers. DBV Technologies’ Phase IIb results of its peanut allergy therapy, Viaskin Peanut, were one of 2016’s biggest clinical success stories when it successfully desensitized children to obviate life-threatening allergies. A trial in children between the ages […]

August 2, 2017 - 1 minutemin - By Evelyn Warner

News and Trends 1 Aug 2017

Potential Herpes Cure from Germany Fast-Tracked for Patients with Weak Immune Systems

AiCuris’ Pritelivir has now secured FDA endorsement in the form of a Fast Track Designation in immuno-compromised patients. Based in Wuppertal, Germany, and spun out from Bayer, AiCuris is focused on curing infectious diseases. Its lead candidate for herpes simplex viruses 1 and 2 (HSV-1 and -2), pritelivir, has been watched closely for its promise […]

August 1, 2017 - 2 minutesmins - By Editorial Team

News and Trends 28 Jul 2017

Things are Looking Up for UK Synbio Clusters, says Report

A survey of synbio startups in the last 16 years shows that the UK ecosystem is growing rapidly and approaching critical mass, says SynbiCITE. Dedicated to championing industrial uptake of synthetic biology, SynbiCITE is a knowledge center based at Imperial College London. Some of its initiatives have included opening a gene foundry last year to providing grants to […]

July 28, 2017 - 3 minutesmins - By Denise Neves Gameiro

Cancer immunotherapy resistance mechanism University Hospital Zurich

News and Trends 27 Jul 2017

Swiss Researchers Unveil Cancer Immunotherapy Resistance Mechanism

Scientists from the University of Zurich have identified an epigenetic control switch responsible for turning melanoma unresponsive to immune checkpoint inhibitors. A study published this week in Cell Reports describes a mechanism that might be responsible for the development of resistance to cancer immunotherapy. The culprit turned out to be Ezh2, a protein that controls genetic […]

July 27, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

UK Pharma Pays Over €200M for a German Drug Against Biliary Cancer

Cancer Research UK Teams Up with London Startup in Immuno-oncology

Belgian Biotech Takes Down Untreatable Lung Disease in Phase II, Eyes the Market

UK Cannabinoid Company Loses 9% and a Competitor after American Phase II Failure

Danish Diabetes Biotech Rakes in $75M on NASDAQ in American IPO

Demo Day: Meet the Latest Generation of Synbio Startups from RebelBio

Designer Babies in Europe: German Merck Set to Receive CRISPR Patent

Scottish Biotech gets €4M from Horizon 2020 for Off-the-Shelf Cell Therapy

French Biotech May Save Toddlers from Life-Threatening Peanut Allergy

Potential Herpes Cure from Germany Fast-Tracked for Patients with Weak Immune Systems

Things are Looking Up for UK Synbio Clusters, says Report

Swiss Researchers Unveil Cancer Immunotherapy Resistance Mechanism

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!